Antibody-drug conjugates are evolving from promising concepts to precisely engineered solutions, unlocking new possibilities for targeted oncology therapies. Design advancements such as enhanced linker-payload engineering and refined target selection are improving efficacy, safety and trial viability.

Join experts from IQVIA Biotech and IQVIA as they pull back the curtain on the science behind ADC innovations, clarify the regulatory requirements and share practical trial strategies aimed at accelerating patient access to new treatments.

Key Takeaways:

• Apply design enhancements to develop effective trial strategies, including enrichment techniques and endpoint selection
• Understand the shifting regulatory landscape for ADCs and address its challenges
• Interpret market trends to help position your programs for faster development

Panel:

Erin Finot, MS, MBA, Vice President of Immuno-Oncology and CAGT, IQVIA Biotech

Jeffrey Hodge, MS, Vice President, Early Phase Oncology and Precision Medicine, Hematology, Oncology Center of Excellence, IQVIA

Brad Smith, Ph.D., Vice President, Therapeutic Strategy IQVIA

For more information and to register, click here.